| ²é¿´: 247 | »Ø¸´: 0 | |||
690820286½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
Ó¢ÎÄ·Òë̽ÌÖ
|
|
Safety assessment studies to qualify an impurity should compare the new drug substance containing a representative amount of the new impurity with previously qualified material. Safety assessment studies using a sample of the isolated impurity can also be considered. ÕâÁ½¾ä»°Ó¦¸ÃÈçºÎÀí½â |
» ²ÂÄãϲ»¶
298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
302Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
»¯Ñ§¹¤³Ì321·ÖÇóµ÷¼Á
ÒѾÓÐ17È˻ظ´
344Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
312Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸Ìì½ò´óѧ»¯Ñ§¹¤ÒÕרҵ£¨081702£©315·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
288Çóµ÷¼Á£¬Ò»Ö¾Ô¸»ªÄÏÀí¹¤´óѧ071005
ÒѾÓÐ4È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
ÕÒµ½Ò»Ð©Ïà¹ØµÄ¾«»ªÌû×Ó£¬Ï£ÍûÓÐÓÃŶ~
ÇóÑо¿Ô±ÏµÁÐÖ°³ÆµÄÓ¢ÎÄ·Òë
ÒѾÓÐ1È˻ظ´
¸±Ê³Æ·¹«Ë¾¼ò½éÓ¢ÎÄ·Òë
ÒѾÓÐ9È˻ظ´
Ó¢ÎÄ׍ָ·Òë³ÉÖÐÎÄ
ÒѾÓÐ8È˻ظ´
Öйú¸÷Àà»ù½ð×ÊÖúÏîĿӢÎÄ·Ò루ÖÐÓ¢ÎĶÔÕÕ£©£¨×ª£©
ÒѾÓÐ9È˻ظ´
¡¶·ÖÎö»¯Ñ§¡·ÓëElsevierºÏ×÷³ö°æµÄÓ¢ÎÄ·Òë¸åÊÇ×Ô¼º·Ò룿»¹Êdzö³ö°æÉ縺Ôð·Ò룿
ÒѾÓÐ4È˻ظ´
ÇóÖú·ÒëÒ»¾äÓ¢ÎÄ£¬Ò©ÎïÁÙ´²Ñо¿·½ÃæµÄ£¬Ð»Ð»
ÒѾÓÐ6È˻ظ´
дӢÎÄÎÄÕ£¬ÊÇÓ¢ÒëÖл¹ÊÇÖ±½ÓÉÏÓ¢ÎÄ£¿£¿£¿
ÒѾÓÐ39È˻ظ´
Ó¢ÎÄ·Òë³ÉÖÐÎÄËã³Ï®Âð
ÒѾÓÐ14È˻ظ´
´ó¼ÒÔõôд×Ô¼ºµÄµÚһƪӢÎÄÎÄÕµģ¿
ÒѾÓÐ32È˻ظ´
У¶ÔÒâ¼ûÖС°ÖÐÎĵÄÎÄÏ×ÄÚÈÝÒªÓÐÏà¶ÔÓ¦µÄÓ¢ÎÄ·Ò롱ÊÇʲôÒâ˼£¬¼±£¡
ÒѾÓÐ3È˻ظ´
Öйú¿ÆÑ§ÖÐÎļÓÃÁË£¬ÊDz»ÊÇÒ»¶¨Òª·Òë³ÉÓ¢ÎÄÔÙ·¢±í£¿
ÒѾÓÐ24È˻ظ´
ͶӢÎÄÎÄÕÂÔõô·ÒëµÄ£¿
ÒѾÓÐ16È˻ظ´
¿ÆÑдÓСľ³æ¿ªÊ¼£¬ÈËÈËΪÎÒ£¬ÎÒΪÈËÈË













»Ø¸´´ËÂ¥
µã»÷ÕâÀïËÑË÷¸ü¶àÏà¹Ø×ÊÔ´